Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGB5RE)

• Drug Name: Tranylcypromine Drug Info
• Synonyms: GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Approved	[1]
Prostate cancer	2C82.0	Patented	[2]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 19493
  ChEBI ID: CHEMBL94631
  CAS Number: CAS 3721-26-4
  TTD Drug ID: DMGB5RE
  ACDINA Drug ID: D00697

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase (MAO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[2]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[2]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[2]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[6]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[2]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[2]
Ergoloid mesylate	DMORPBA	Alzheimer disease	8A20	Approved	[7]
Cyclopropylamine derivative 11	DMMJ0YN	N. A.	N. A.	Patented	[8]
PMID27019002-Compound-20a	DMRX748	N. A.	N. A.	Patented	[8]
Cyclopropylamine derivative 9	DMX7YAL	N. A.	N. A.	Patented	[8]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[9]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[10]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[11]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[12]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[13]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[14]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[15]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[1]
Budipine	DMODHQI	Migraine	8A80	Approved	[16]
Safinamide	DM0YWJC	Parkinson disease	8A00.0	Approved	[17]

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[18]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[19]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[20]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[21]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[22]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[23]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[24]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[25]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[26]
Desoxypeganine	DMTR7EH	Alcohol dependence	6C40.2	Phase 1	[27]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[28]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[29]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[30]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[31]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[32]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[33]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[34]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[33]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[29]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[35]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[2]
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[3]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[5]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [3] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [4] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [5] Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol. 2004 Aug 23;497(2):223-31.
• [6] Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
• [9] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [10] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [12] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [13] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [14] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [15] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [16] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [17] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [18] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [19] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [20] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [21] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [22] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [23] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [24] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [25] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [26] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
• [27] Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
• [28] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [29] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [30] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [31] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [32] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [33] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [34] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [35] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.